These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 34970153)
1. Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer. Chongqing T; Sini L; Xiaohui Z; Liubao P; Ye P; Shuxia Q; Liting W; Meiyu W; Xiaomin W Front Pharmacol; 2021; 12():802942. PubMed ID: 34970153 [No Abstract] [Full Text] [Related]
2. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system. Zhu C; Han G; Wu B BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer. Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. Liu T; Liu S; Guan S; Tai Y; Jin Y; Dong M J Chemother; 2023 Dec; 35(8):745-752. PubMed ID: 36591729 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK. McCarthy G; Young K; Madin-Warburton M; Mantaian T; Brook E; Metcalfe K; Mikelson J; Xu R; Seyla-Hammer C; Aguiar-Ibáñez R; Amonkar M J Med Econ; 2024; 27(1):279-291. PubMed ID: 38293714 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer. Huo G; Song Y; Chen P J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38606826 [TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis. Zhu Y; Liu K; Zhu H Int J Gynecol Cancer; 2024 Jun; ():. PubMed ID: 38901970 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis. Zhu Y; Liu K; Zhu H J Gynecol Oncol; 2024 Jun; ():. PubMed ID: 38857909 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan. Sugiura K; Hiratsuka H; Oshima G; Aiko S Jpn J Clin Oncol; 2023 Jul; 53(8):691-697. PubMed ID: 37259600 [TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497 [TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA; N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544 [TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China. Ma Y; Zhou J; Ye Y; Wang X; Ma A; Li H Front Oncol; 2023; 13():1113346. PubMed ID: 37182176 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF. Giuliani J; Mandara M; Mantoan B; Ferrario L; Mangiola D; Napoli G; Muraro M; Fiorica F J Oncol Pharm Pract; 2023 Jun; 29(4):958-961. PubMed ID: 36823960 [TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis. Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer. Yoshino T; Andre T; Kim TW; Yong WP; Shiu KK; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Alcaide-Garcia J; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Le DT; Adachi N; Fogelman D; Marinello P; Diaz LA Cancer Sci; 2023 Mar; 114(3):1026-1036. PubMed ID: 36369901 [TBL] [Abstract][Full Text] [Related]
19. The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. Trullas A; Delgado J; Genazzani A; Mueller-Berghaus J; Migali C; Müller-Egert S; Zander H; Enzmann H; Pignatti F ESMO Open; 2021 Jun; 6(3):100145. PubMed ID: 33940347 [TBL] [Abstract][Full Text] [Related]
20. Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study. Chen Y; Martin P; Inoue LYT; Basu A; Carlson JJ Value Health; 2024 Jul; 27(7):926-935. PubMed ID: 38548177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]